Connexin43, A Promising Target to Reduce Cardiac Arrhythmia Burden in Pulmonary Arterial Hypertension
Open Access
- 14 March 2024
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (6) , 3275
Abstract
While essential hypertension (HTN) is very prevalent, pulmonary arterial hypertension (PAH) is very rare in the general population. However, due to progressive heart failure, prognoses and survival rates are much worse in PAH. Patients with PAH are at a higher risk of developing supraventricular arrhythmias and malignant ventricular arrhythmias. The latter underlie sudden cardiac death regardless of the mechanical cardiac dysfunction. Systemic chronic inflammation and oxidative stress are causal factors that increase the risk of the occurrence of cardiac arrhythmias in hypertension. These stressful factors contribute to endothelial dysfunction and arterial pressure overload, resulting in the development of cardiac pro-arrhythmic conditions, including myocardial structural, ion channel and connexin43 (Cx43) channel remodeling and their dysfunction. Myocardial fibrosis appears to be a crucial proarrhythmic substrate linked with myocardial electrical instability due to the downregulation and abnormal topology of electrical coupling protein Cx43. Furthermore, these conditions promote ventricular mechanical dysfunction and heart failure. The treatment algorithm in HTN is superior to PAH, likely due to the paucity of comprehensive pathomechanisms and causal factors for a multitargeted approach in PAH. The intention of this review is to provide information regarding the role of Cx43 in the development of cardiac arrhythmias in hypertensive heart disease. Furthermore, information on the progress of therapy in terms of its cardioprotective and potentially antiarrhythmic effects is included. Specifically, the benefits of sodium glucose co-transporter inhibitors (SGLT2i), as well as sotatercept, pirfenidone, ranolazine, nintedanib, mirabegron and melatonin are discussed. Discovering novel therapeutic and antiarrhythmic strategies may be challenging for further research. Undoubtedly, such research should include protection of the heart from inflammation and oxidative stress, as these are primary pro-arrhythmic factors that jeopardize cardiac Cx43 homeostasis, the integrity of intercalated disk and extracellular matrix, and, thereby, heart function.Keywords
Funding Information
- VEGA (2/0006/23, 2/0133/24, 21-0410)
- Slovak Research and Development Agency (2/0006/23, 2/0133/24, 21-0410)
This publication has 186 references indexed in Scilit:
- The UPHILL study: A nutrition and lifestyle intervention to improve quality of life for patients with pulmonary arterial hypertensionPulmonary Circulation, 2023
- β3 Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Associated with Heart Failure (SPHERE-HF): A Double Blind, Placebo-Controlled, Randomized Clinical TrialEuropean Journal of Heart Failure, 2022
- Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection FractionJAMA Cardiology, 2022
- Nutritional status in pulmonary arterial hypertensionPulmonary Circulation, 2022
- Acute Pleiotropic Effects of Dapagliflozin in Type 2 Diabetic Patients with Heart Failure with Reduced Ejection Fraction: A Crossover TrialESC Heart Failure, 2021
- German Cardiac Society Working Group on Cellular Electrophysiology state-of-the-art paper: impact of molecular mechanisms on clinical arrhythmia managementClinical Research in Cardiology, 2018
- Ventricular tachycardias in patients with pulmonary hypertension: an underestimated prevalence? A prospective clinical studyHerzschrittmachertherapie + Elektrophysiologie, 2015
- Progressive right ventricular functional and structural changes in a mouse model of pulmonary arterial hypertensionPhysiological Reports, 2013
- Improving cardiac gap junction communication as a new antiarrhythmic mechanism: the action of antiarrhythmic peptidesNaunyn-Schmiedeberg's Archives of Pharmacology, 2009
- Differences in distribution of fibrosis in the ventricles underlie dominant arrhythmia vulnerability of the right ventricle in senescent miceNetherlands Heart Journal, 2008